AstraZeneca launches full-cycle production of Forxiga in Russia

15 December 2020

UK pharma major AstraZeneca (LSE: AZN) has announced the launch of full-cycle production of Forxiga (dapagliflozin), its drug designed for the treatment of adult patients with type 2 diabetes mellitus and chronic heart failure, in Russia at the facilities of its local plant in the Kaluga region, according to recent statements, made by the company and the regional authorities, reports The Pharma Letter’s local correspondent.

The company considers the project as important at the mortality from circulatory system diseases (CVD) in Russia currently remains high, estimated at 573 cases per 100,000 people. Of these, a significant part accounts for chronic heart failures. In Russia, this disease affects about 10 million people.

With regard to type 2 diabetes mellitus (T2DM), it currently represents one of the leading conditions in the structure of non-communicable chronic diseases, both in Russia and in the world. Today in Russia the real number of patients with type 2 diabetes is about 9 million people (about 6% of the population).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK